Abstract BCR-ABL-negative primary myelofibrosis (PMF) shows non-specific karyotype abnormalities in up to 30 % of patients, e.g. chromosome 7 defects, which are associated with an adverse prognosis. The impact of chromosome 7 aberrations on cell pathobiology is not yet known. We speculated that chromosome 7q-encoded regulatory microRNA might be one possible basis of instable disease. JAK2
Introduction
Philadelphia chromosome-negative myeloproliferative neoplasms (Ph − MPN) can acquire cytogenetic defects [1] . In particular, in primary myelofibrosis (PMF), up to 30 % of patients have an aberrant somatic karyotype in their neoplastic haematopoiesis, while in non-fibrosing polycythemia vera (PV) and essential thrombocythemia (ET), the frequency is lower. Recurrent defects are +8, +9, del(13q) and del(20q), but these chromosomal aberrations are not specific for PMF [1, 2] . They can be also found in other Ph − MPN entities and as secondary alterations in Ph + chronic myelogenous leukaemia (CML), in myelodysplastic syndromes (MDS) and acute myeloid leukaemias (AML) [1] [2] [3] [4] . It has been shown that the presence of similar types of karyotype anomalies in MDS and PMF, in particular −7/del(7q), is associated with an adverse prognosis (lower survival rates and a higher rate of secondary AML transformation) [4] [5] [6] [7] [8] . It is not fully understood why these chromosome 7 aberrations have such an impact on cell pathobiology [3, 9] . Besides protein-coding genes, hundreds of microRNA genes are encoded on autosomal chromosomes and the X chromosome [10] [11] [12] . Precursor transcripts (100-150 nucleotides in length) from these genes are processed to 20-25-nucleotide short RNA molecules, the biologically active mature microRNAs [10] [11] [12] . These RNA molecules bind in a semi-complementary fashion to the 3′-untranslated region (3′-UTR) of mRNA molecules which inhibits protein translation and therefore represents a complex regulatory system of cell homeostasis in normal and neoplastic tissues [10] [11] [12] . The role of microRNAs appears to be more a modulation of Electronic supplementary material The online version of this article (doi:10.1007/s12308-015-0258-z) contains supplementary material, which is available to authorized users. mRNA/protein translation and not a complete suppression [10] [11] [12] .
MicroRNA expression analyses have been performed in chronic stage MPN, including PMF, but have not been correlated with underlying chromosomal defects [13] [14] [15] [16] [17] . At least in one post-PMF AML case with t(12;18)(p13.2;q12.3), it has been demonstrated that expression of 18q12.3-encoded miR-4319 is decreased [18] . In MDS with del(5q), chronic lymphocytic B cell leukaemia with del(13q) and splenic marginal zone lymphoma with del(7q32) there are hints that microRNAs which are encoded on the deleted chromosome segment can be involved in mediation of disease phenotypes [19] [20] [21] . In contrast to monogenic neoplasms which are based on one single or at least one major defect, e.g. CML, no haematopoietic or solid organ neoplasm has been identified in which one single microRNA is the disease-causing aberration [10] [11] [12] . Therefore, a shift of the total microRNA expression profile rather than deregulation of one single microRNA is more likely to have a pathobiological effect on cell homeostasis in MPN. In this analysis, we aimed to evaluate whether such a shift could be related to chromosome 7q defects in PMF.
Materials and methods

Study groups
Study group I (microRNA profiling): PMF samples for screening of karyotype-associated microRNA profiles represent a relatively homogeneous group which mainly differ by their karyotypes (n = 10). All cases had advanced stage fibrosis and osteosclerosis (MF3), myeloblasts were <5 % in all cases, and all cases were JAK2 V617F -positive. DNA extraction and PCR-based JAK2 V617F mutation analysis with a pyrosequencer device were performed as previously described [22] . The microRNA expression profile was tested in PMF without karyotype aberrations (n = 3), PMF with isolated del(7q) (n = 2), translocations affecting 7q (n = 2), and PMF with non-7 aberrations (n = 3). As previously published, JAK2 V617F -negative PMF with chromosome 7 defects could not be identified in our cohort [2] . For control purposes, a pool of three age-matched cases with non-neoplastic haematopoiesis was analysed ( Table 1, supplementary  Table 1 ).
Study group II (re-evaluation of single microRNA and target mRNA): Re-evaluation was performed for single gene transcripts in a second cohort of MPN and controls (n = 50). Each 10 pre-fibrotic PMF (MF0, all with normal karyotypes), fibrotic PMF (MF2-3, 7/10 with normal karyotype, 3/10 not tested), PV (MF0, two with non-7 defects, all others normal karyotypes), ET (MF0, all normal karyotypes) and nonneoplastic controls were analysed (Table 1 ).
All samples, including controls, were collected as part of standard clinical care for evaluation of bone marrow status. Bone marrow trephines were formalin-fixed and paraffinembedded (FFPE) and were retrieved from the tissue registry of the Institute of Pathology, Hannover Medical School. The study was approved by the local ethics committee.
MicroRNA profiles in PMF with cytogenetic aberrations RNA was isolated from bone marrow cells by proteinase K digestion and phenol/chloroform extraction as described [23, 24] . MicroRNA profiling was performed by using 3 μl/1 ng of the RNA solution for reverse transcription in 7.5 μl reactions (TaqMan Megaplex Pools with Preamplification, Applied Biosystems, Foster City, CA, USA). Similar to our previous study [24] , as a non-neoplastic reference, RNA from three cases with normal haematopoiesis was pooled. TaqMan Array Human MicroRNA Panel A which includes 378 microRNA and three endogenous control genes (small nucleolar RNA, C/D box 48/RNU48 which is encoded on segment 6p21.33; RNU44, 1q25.1; RNA, U6 small nuclear 1/U6, 15q23) were loaded with a mixture of 1 part diluted PreAmp product (1:4), 9 parts H 2 O and 50 parts Universal PCR Master Mix (Applied Biosystems). The real-time PCR runs were performed on a 7900HT Fast Real-time PCR system (Applied Biosystems).
Re-evaluation of miR-146b and potential targets in MPN
Bone marrow-derived RNA was used in the second cohort for measuring the expression of the 10q24.32-encoded miR-146b (endogenous control RNU48). In addition, two potential miR146b target molecules, matrix metallopeptidase 16 (MMP16, encoded on segment 8q21.3) and tissue inhibitor of metallopeptidases 4 (TIMP4, 3p25) and endogenous control gene polymerase (RNA) II (DNA-directed) polypeptide A, 220 kDa (POLR2A, 17p31.1) were evaluated from the same RNA (TaqMan Assays, ABI PRISM 7500 Sequence Detector, both Applied Biosystems) [23, 24] .
Data analysis
C T values were converted into ΔC T values (endogenous control gene: RNU48 for microRNA and POLR2A for mRNA) and further into 2 -ΔCT (normalized against RNU48 and POLR2A, respectively). As a pre-screening, expression levels of cohort I were sorted according to the levels of nonneoplastic control pool data and the mean values of each of the three cytogenetic PMF groups. Arbitrary, mean foldchanges of >2 were considered as up-and down-regulation. PMF groups were compared to each other with the nonparametric Kruskal-Wallis test followed by Dunn's post test and exact p values were determined with the two-tailed Mann-Whitney test (Prism 5.0, GraphPad Software, San Diego, CA, USA). Cluster analysis of microRNA profiles was performed with the Qlucore Omics Explorer 2.2 (Qlucore AB, Lund, Sweden).
In cohort II, transcript expression levels of single genes were compared with the Kruskal-Wallis and Dunn's post test followed by the two-tailed Mann-Whitney test (Prism 5.0). Correlation analysis of miR-146b/TIMP4 levels was performed with Spearman's test (Prism 5.0). P values <0.05 were considered statistically significant.
Results
No chromosome 7q-related microRNA expression profile in PMF
The particular underlying chromosomal defects were correlated with the expression of microRNAs which are encoded on the chromosome segments involved. Chromosome 7q-encoded microRNA, such as miR-25 (7q22.1), miR-93 (7q22.1), miR-106b (7q22.1), miR-96 (7q32.2), miR-182 (7q32.2), miR-183 (7q32.2), miR-335 (7q32.2) and miR-29a (7q32.3), were not specifically deregulated in PMF with 7q21-35 defects (Fig. 1, supplementary Table 2 ). Cluster analyses revealed an expression profile which could not discriminate PMF with different karyotype aberrations and normal karyotypes.
Compared with normal bone marrow cells, PMF with chromosome 7q defects but also PMF with non-7q defects showed a tendency towards lower levels of the miR-17 precursor family, which includes miR-17 (encoded on chromosome segment 13q31.3), miR-20a (13q31.3), miR-20b (Xq26.2), miR106a (Xq26.2), miR-106b (7q22.1) and miR-93 (7q22.1). Compared with the control pool, PMF with normal karyotypes mainly had similar levels of miR-17 precursor family members (supplementary Table 2 ). Therefore, the cytogenetic defects under investigation have no direct effect on the microRNA expression profile in PMF with chromosome 7q defects.
Increased miR-146b expression in PMF is independent from chromosomal defects
In non-neoplastic bone marrow cells, a total of 24 microRNAs were expressed with a relative level of ≥1 (supplementary Table 2 ). Similar to previous results [11, 12] , the microRNA with the highest expression level was miR-223.
Independent of the chromosomal defects, in general, in PMF, the 17q22-encoded miR-142-3p and miR-208b (14q11.2) showed lower expression levels as well as higher levels of miR-146b (10q24.32) (Fig. 1 supplementary Table 2 ). We selected miR-146b for re-evaluation in the second cohort because this microRNA is linked to the regulation of fibrosis-associated factors, such as MMP16 and TIMP4 [25, 26] . Therefore, the transcript expressions of these two genes were also analysed. We found that a subfraction of fibrotic stage PMF overexpressed miR-146b (versus nonneoplastic controls p < 0.0001; versus pre-fibrotic PMF, PV and ET each p ≤ 0.02). MMP16 transcripts could not be detected. TIMP4 was expressed at higher levels in fibrotic stage PMF, but the differences were not significant (Fig. 1) . No negative correlation between miR-146b and TIMP4 was found, indicating no direct negative regulation.
Discussion
Based on previous results on haematopoietic neoplasms, we hypothesized that a deletion of a chromosomal region could lead to decreased gene expression of encoded microRNA. Low grade B cell lymphomas with del(7q32) show lower levels of 7q32-encoded miR-29a and miR-29b-1 [21] . In contrast to lymphomas, we could not find a direct effect of chromosome 7q defects and deregulated expression of 7q-encoded microRNA in PMF. It has been shown in MDS that the expression of microRNAs and protein-coding mRNA transcripts can be related to chromosome 7 or del(5q) defects, but the corresponding genes are mainly not 7-or 5q-encoded [7, 23, 24, [27] [28] [29] . For example, there are new data that show that MDS-del(5q) shows aberrant expression profiles of several 14q-encoded microRNAs [29] . This indicates that microRNA expression could be transregulated, e.g. hypermethylation of a 9p-encoded gene is found more often in MDS with −7 [7] or in t(9;22)(q34;q11)-positive CML, the chromosome 17q-encoded miR-451 can bind to BCR-ABL fusion mRNA while BCR-ABL protein suppresses transcription of miR-451 [17] . Although we could not prove our hypothesis of a chromosome 7q-related microRNA expression profile in PMF, we noted that, independent of the underlying karyotype, fibrotic stage PMF showed higher levels of 10q-encoded miR-146b. In a second cohort, we could confirm an association of fibrosis and increased miR-146b levels. Furthermore, a recent study from Korea also revealed increased miR-146b expression in PMF bone marrow cells [30] . In PMF-derived CD34 + cells, miR-146b is also increased while the megakaryocytic differentiation of PMF-derived CD34 + cells is paralleled by increase of 21q-encoded miR-155 levels [15] . Previously, we could show that PMF bone marrow-derived megakaryocytes have an increased miR-146b expression in situ but not miR-155 [14] . While bone marrow megakaryocytes and CD34+ cells express miR-146b, this microRNA is not increased in the peripheral blood of PMF patients [31] . This could indicate that miR-146b plays a role in the modulation of the bone marrow microenvironment, i.e. in megakaryocytic cell homeostasis, and not in circulating leukocytes and platelets. In In the screening cohort I, all PMF cases were in advanced fibrotic stages. e-g MiR-146a was moderately increased in some PMF while its paralogue miR-146b showed a tendency for high levels in fibrotic PMF. Re-evaluation (cohort II) confirmed that fibrotic stage PMF cases express high or very high levels of miR-146b. The difference was significant: PMF MF2-3 (mean relative expression level 11.85, standard deviation ±11.89) versus PMF MF0 (3.21 ± 1.33; p = 0.02*), PV (2.07 ± 1.16; p = 0.002**), ET (1.91 ± 1.22; p = 0.0007***) and controls (0.70 ± 0.43; p < 0.0001***). Furthermore, PMF MF0 (p < 0.0001***), PV (p = 0.0007***) and ET (p = 0.0089***) had significantly higher levels than controls. h TIMP4 was increased in fibrotic stage PMF (not significant) and no negative miR-146b/TIMP4 correlation was found (Pearson r = 0.4). Abbreviations: PMF MF3 cases with 7q defects (PMF, 7q), with non-7q defects (PMF, non-7q) and with normal karyotypes (PMF, NK), pool of three non-neoplastic controls with normal karyotypes, cohort I (C, pool), grade of fibrosis in fibrotic PMF, pre-fibrotic PMF, PV and ET without fibrosis, cohort II (MF 0-3), non-neoplastic control cases, cohort II (C) principle, increased miR-146b expression could contribute to fibrosis, e.g. by interfering in the MMP16/MMP2 axis or by inhibiting TIMP4 and SMAD family member 4 (SMAD4) transcripts [25, 26, 32] . Secreted MMP16 activates MMP2 by cleavage in the extracellular matrix and MMP2 degrades type IV collagen and increased miR-146b can alter these protein interactions [25] . We could show that MMP2 is increased and not decreased in fibrotic stage PMF [33] , but in this current analysis, we could not detect MMP16 transcripts in MPN and non-neoplastic haematopoiesis. Therefore, we found no evidence of an miR-146b/MMP16 deregulation. SMAD4 is an intracellular factor which is related to the transforming growth factor (TGF) beta-induced signalling. We could previously show that the TGF beta type II receptor (TGFR2) is increased in advanced stage PMF while SMAD4 is not deregulated on the transcript level [33] which makes a relevant miR-146b/SMAD4 deregulation unlikely. It has been shown that miR-146b/TIMP4 regulation is associated with atrial fibrosis [26] , and we therefore evaluated whether this molecular mechanism could be found also in fibrotic stage PMF. Although we found no direct miR-146b/TIMP4 regulation on the transcript level in PMF, a modulation of the mRNA/ protein translation could be possible [26] . Therefore, a subfraction of fibrotic stage PMF shows an increased miR146b expression but the major fibrosis-associated molecular defect remains to be identified.
In summary, in PMF bone marrow cells, the expression of 7q-encoded microRNAs is not related to defects of chromosome segment 7q while microRNAs, such as miR-146b, which are encoded on other chromosome segments, can be deregulated.
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